Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
link
photo
Tags
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
boston
boston blog main
boston top stories
clinical trials
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
gene therapy
joshua brumm
kaleido biosciences
life sciences
muscular dystrophy
myotonic dystrophy type 1
national blog main
national top stories
new york blog main
rare disease drugs
romesh subramanian
san diego blog main
san francisco blog main
susanna high
vertex pharmaceuticals
What
expected
3
×
genetic
having
3
×
rare
beef
bills
disease
doctors
gene
genome
instead
marker
maybe
medical
patients
person
sequenced
symptoms
test
ago
biotechs
considering
data
diseases
drug
dyne
early
experimental
eyes
humans
ipo
ipos
long
medicines
muscle
reach
therapeutics
worked
Language
unset
Current search:
expected
×
having
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@WIRED
6 years ago
When doctors genome sequenced 50 test patients, they expected to find *maybe* one person with a genetic disease marker. Instead, they found 11.
@WIRED
6 years ago
When doctors genome sequenced 50 test patients, they expected to find *maybe* one person with a genetic disease marker. Instead, they found 11.
